Latest AtaiBeckley News & Updates

See the latest news and media coverage for AtaiBeckley. We track all announcements, press releases, and industry mentions in real time, all in one place.

AtaiBeckley

Mental health therapeutics developer

ataibeckley.com

Headquarters: New York, United States
Company type: Public company
Number of employees: 100–200
Industry: Pharmaceuticals

Last updated Today

Latest news about AtaiBeckley

In short: AtaiBeckley was acquired by Eli Lilly for up to $3.8 billion, completing its merger and delisting from Nasdaq.

Company announcements

September 11 AtaiBeckley

Eli Lilly acquires AtaiBeckley

The acquisition advances a pipeline of rapid-acting neuroplastogens for treatment-resistant depression and other serious mental health conditions.

July 16 AtaiBeckley

AtaiBeckley acquired by Lilly for $2.8 billion

The deal includes potential milestone payments and expands Lilly's neuroscience pipeline for treatment-resistant depression.

July 6 AtaiBeckley

AtaiBeckley completes enrollment in VLS-01 Phase 2b TRD trial

Topline data due Q4 2026; intends to start Phase 3 for major depressive disorder.

April 22 AtaiBeckley

AtaiBeckley announces additional Phase 2a results for EMP-01

The trial demonstrated clinically meaningful reductions in SAD symptoms and high responder rates with no serious adverse events.

Media coverage

September 11 Stock Titan

AtaiBeckley common stock delisted from Nasdaq | ATAI SEC Filing - Form 25-NSE

Nasdaq moves to strike AtaiBeckley’s common stock from listing under Section 12(b), citing compliance with voluntary withdrawal rules 12d2-2(b) and 12d2-2(c).

September 11 Financial Times

Lilly completes acquisition of AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions

Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of AtaiBeckley Inc. AtaiBeckley is a clinical-stage biopharmaceutical company developing rapid-acting...

August 31 Yahoo Finance

Social anxiety drugs have been floundering in the clinic. Could Eli Lilly help tip the scales?

After two notable failures, the social anxiety R&D space gained a major player when Eli Lilly agreed to acquire AtaiBeckley this year.

August 28 The AI Journal

AtaiBeckley Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of AtaiBeckley Inc. – ATAI

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the...

Never miss news about AtaiBeckley

Track AtaiBeckley and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

AtaiBeckley competitors & trending companies

Browse news for competitors to AtaiBeckley and other trending companies.